Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Final Results from Extension Studies

Semin Thromb Hemost. 2022 Mar;48(2):253-255. doi: 10.1055/s-0041-1740148. Epub 2021 Dec 23.

Authors

Matteo Nicola Dario Di Minno¹, Alessandro Di Minno², Ilenia Calcaterra³, Ernesto Cimino³, Francesco Dell'Aquila³, Massimo Franchini⁴

Affiliations

¹ Department of Translational Medical Sciences, Federico II University, Naples, Italy.
² Dipartimento di Farmacia, Università degli Studi di Napoli "Federico II," Napoli, Italy.
³ Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
⁴ Department of Haematology and Transfusion Medicine, "Carlo Poma" Hospital, Mantua, Italy.

PMID: 34942666
DOI: 10.1055/s-0041-1740148

No abstract available

MeSH terms

Factor IX
Factor VIII* / therapeutic use
Half-Life
Hemophilia A* / drug therapy
Humans

Substances

Factor VIII
Factor IX